Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called clazakizumab (tested at three different doses — 25mg, 100mg, and 200mg) compared with a placebo (a dummy treatment with no active ingredient) in people with psoriatic arthritis. A total of 165 people were enrolled across the four groups, with roughly 41 people in each group at the start. The trial was measuring things like joint tenderness and swelling, skin involvement from psoriasis, physical functioning, and quality of life. The reported data shows that for the main measure — the proportion of people whose joint symptoms improved by at least 20% (a standard arthritis scoring method) at week 16 — 29.3% of the placebo group reached this threshold, compared with 46.3% in the 25mg group, 52.4% in the 100mg group, and 39.0% in the 200mg group. For the secondary measures, the reported data shows that at week 24 the proportions reaching that same joint improvement threshold were 34.1% (placebo), 56.1% (25mg), 57.1% (100mg), and 39.0% (200mg). For a higher level of joint improvement (50%), the figures at week 16 were 7.3% (placebo), 29.3% (25mg), 35.7% (100mg), and 17.1% (200mg). For skin improvement — specifically a 75% reduction in a psoriasis scoring system — the reported figures at week 16 were 14.6% (placebo), 12.2% (25mg), 16.7% (100mg), and 4.9% (200mg). The reported data also shows that for physical functioning (measured by a standard questionnaire where a meaningful improvement is a drop of at least 0.3 points on a 0–3 scale), 36.6% of the placebo group and 48.8%, 45.2%, and 39.0% of the three clazakizumab groups respectively showed that level of improvement at week 16. Quality-of-life scores (on a 0–100 scale where higher means better) showed small changes across all groups, with the data not indicating notably large differences between groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 27059799) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be currently taking Methotrexate (MTX) at a steady dose — you need to have been on it for at least 3 months, at a dose between 15mg and 25mg per week, with no dose change in the 4 weeks before joining (a lower dose of 10mg/week may be allowed in certain circumstances — confirm with trial site)
- You must not have had enough relief from painkillers such as anti-inflammatory drugs (NSAIDs) and/or certain non-biologic disease-modifying medications
- You must have at least 3 swollen joints and at least 3 tender joints at the time of joining
- You must have active psoriasis skin patches covering at least 3% of your body surface area
- You must have a blood test result showing a raised level of a marker of inflammation called hsCRP (at or above 0.3 mg/dL) (confirm with trial site)
Who may not be able to join:
- You cannot join if you have previously received, or are currently receiving, a type of treatment known as a "biologic therapy"
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.